{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["atezolizumab","obinutuzumab","venetoclax"]],"indication":"chronic lymphocytic leukemia, small lymphocytic lymphoma, Richter syndrome","name":"NCT02846623","nct_id":"NCT02846623","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02846623. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.","label":"Cohort I (obinutuzumab, atezolizumab, venetoclax)","type":"EXPERIMENTAL"},{"description":"Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.","label":"Cohort II (obinutuzumab, atezolizumab, venetoclax)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-02-28","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Transformed Chronic Lymphocytic Leukemia","Richter Syndrome","Small Lymphocytic Lymphoma"],"enrollment":{"count":50,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG7446","RO5541267","Tecentriq"],"type":"DRUG"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Obinutuzumab","otherNames":["Anti-CD20 Monoclonal Antibody R7159","GA-101","GA101","Gazyva","huMAB(CD20)","R7159","RO 5072759","RO-5072759","RO5072759"],"type":"BIOLOGICAL"},{"name":"Venetoclax","otherNames":["ABT-0199","ABT-199","ABT199","GDC-0199","RG7601","Venclexta","Venclyxto"],"type":"DRUG"}],"last_update":"2026-08-10","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Minimal residual disease (MRD) negative rate (Cohort I)","timeFrame":"At end of cycle 9"}],"references":[],"start_date":{"date":"2017-01-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome","url":"https://clinicaltrials.gov/study/NCT02846623"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02846623"}